Eisai Signs Russian Manufacturing PactBy
The Japanese pharmaceutical company, Eisai, and PharmStandard, a Russian pharmaceutical company, have signed cooperation agreements relating to the localized production of Eisai products in Russia. These agreements relate to Eisai’s global oncology therapies, Halaven (eribulin) and Lenvima (lenvatinib), as well as the company’s global epilepsy therapy, Fycompa (perampanel).
Under the proposed agreements, important stages in the manufacturing process for both eribulin and lenvatinib will be completed in PharmStandard’s facilities in Ufa, and manufacturing for perampanel will be performed in PharmStandard’s facility in Kursk.
Eribulin was registered in Russia in July 2012 and became accessible for patients with locally advanced or metastatic breast cancer who have progressed after at least one course of chemotherapy for advanced disease from September 2013. Lenvatinib was registered in Russia in December 2015 and will be accessible for treatment of radioactive iodine refractory differentiated thyroid cancer from June 2016. Perampanel was registered in August 2013 in Russia as adjunctive treatment for patients with partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.